Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S.

Cancer Sci. 2019 Jun 4. doi: 10.1111/cas.14089. [Epub ahead of print]

2.

Migration of a hookwire used as a video-assisted thoracoscopic surgery marker into the splenic artery.

Torigoe H, Hirano Y, Ando Y, Washio K.

Gen Thorac Cardiovasc Surg. 2019 May 21. doi: 10.1007/s11748-019-01142-2. [Epub ahead of print]

PMID:
31115803
3.

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.

Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.

PMID:
30952716
4.

Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.

Int J Oncol. 2019 Jun;54(6):2139-2148. doi: 10.3892/ijo.2019.4768. Epub 2019 Apr 1.

PMID:
30942424
5.

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations.

Ogoshi Y, Shien K, Yoshioka T, Torigoe H, Sato H, Sakaguchi M, Tomida S, Namba K, Kurihara E, Takahashi Y, Suzawa K, Yamamoto H, Soh J, Toyooka S.

Oncol Lett. 2019 Mar;17(3):2729-2736. doi: 10.3892/ol.2019.9908. Epub 2019 Jan 8.

6.

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.

Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S.

BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.

7.

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.

Mol Cancer Res. 2019 Feb;17(2):499-507. doi: 10.1158/1541-7786.MCR-18-0628. Epub 2018 Nov 21.

PMID:
30463991
8.

Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jul 15;145(2):569-575. doi: 10.1002/ijc.31982. Epub 2018 Dec 14.

PMID:
30414170
9.

exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jun 15;144(12):3138-3145. doi: 10.1002/ijc.31945. Epub 2018 Dec 4.

PMID:
30365872
10.

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.

Takahashi Y, Shien K, Tomida S, Oda S, Matsubara T, Sato H, Suzawa K, Kurihara E, Ogoshi Y, Namba K, Yoshioka T, Torigoe H, Yamamoto H, Soh J, Toyooka S.

Cancer Sci. 2018 Nov;109(11):3634-3642. doi: 10.1111/cas.13797. Epub 2018 Oct 6.

11.

Targeting miR-223 in neutrophils enhances the clearance of Staphylococcus aureus in infected wounds.

de Kerckhove M, Tanaka K, Umehara T, Okamoto M, Kanematsu S, Hayashi H, Yano H, Nishiura S, Tooyama S, Matsubayashi Y, Komatsu T, Park S, Okada Y, Takahashi R, Kawano Y, Hanawa T, Iwasaki K, Nozaki T, Torigoe H, Ikematsu K, Suzuki Y, Tanaka K, Martin P, Shimokawa I, Mori R.

EMBO Mol Med. 2018 Oct;10(10). pii: e9024. doi: 10.15252/emmm.201809024.

12.

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.

Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.

Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14.

13.

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.

Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Carcinogenesis. 2018 May 3;39(5):719-727. doi: 10.1093/carcin/bgy044.

PMID:
29546323
14.

Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.

Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Cancer Sci. 2018 May;109(5):1493-1502. doi: 10.1111/cas.13571. Epub 2018 Apr 15.

15.

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S.

Cancer Sci. 2018 Apr;109(4):1166-1176. doi: 10.1111/cas.13546. Epub 2018 Mar 25.

16.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

17.

Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

J Thorac Dis. 2017 Sep;9(9):3076-3086. doi: 10.21037/jtd.2017.08.87.

18.

Conjugation of two RNA aptamers improves binding affinity to AML1 Runt domain.

Nomura Y, Yamazaki K, Amano R, Takada K, Nagata T, Kobayashi N, Tanaka Y, Fukunaga J, Katahira M, Kozu T, Nakamura Y, Haishima Y, Torigoe H, Sakamoto T.

J Biochem. 2017 Dec 1;162(6):431-436. doi: 10.1093/jb/mvx049.

PMID:
28992043
19.

Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, Torigoe H, Watanabe M, Namba K, Yamamoto H, Soh J, Asano H, Miyoshi S, Toyooka S.

Oncol Lett. 2017 Oct;14(4):4349-4354. doi: 10.3892/ol.2017.6678. Epub 2017 Jul 26.

20.

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.

21.

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.

Sato H, Shien K, Tomida S, Okayasu K, Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.

Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.

22.

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.

Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S.

Sci Rep. 2016 Dec 23;6:39557. doi: 10.1038/srep39557.

23.

Usefulness of Thoracoscopic Debridement for Chronic Empyema after an Extrapleural Pneumonectomy.

Torigoe H, Toyooka S, Yamamoto H, Soh J, Miyoshi S.

Acta Med Okayama. 2016 Dec;70(6):507-510.

24.

Material Exhibiting Efficient CO2 Adsorption at Room Temperature for Concentrations Lower Than 1000 ppm: Elucidation of the State of Barium Ion Exchanged in an MFI-Type Zeolite.

Itadani A, Oda A, Torigoe H, Ohkubo T, Sato M, Kobayashi H, Kuroda Y.

ACS Appl Mater Interfaces. 2016 Apr 6;8(13):8821-33. doi: 10.1021/acsami.6b00909. Epub 2016 Mar 28.

PMID:
26990497
25.

[Cross-sectoral Approach of a Perioperative Management Center for General Thoracic Surgery].

Shimoda A, Soh J, Ashiba T, Murata N, Fukuda T, Kobayashi M, Torigoe H, Maki Y, Sugimoto S, Yamane M, Toyooka S, Oto T, Miyoshi S.

Kyobu Geka. 2016 Jan;69(1):20-4. Japanese.

PMID:
26975638
26.

Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient.

Torigoe H, Toyooka S, Katsui K, Soh J, Maki Y, Kiura K, Miyoshi S.

Acta Med Okayama. 2016;70(1):63-5.

27.

The crystal structure of a 2',4'-BNA(NC)[N-Me]-modified antisense gapmer in complex with the target RNA.

Kondo J, Nomura Y, Kitahara Y, Obika S, Torigoe H.

Chem Commun (Camb). 2016 Feb 7;52(11):2354-7. doi: 10.1039/c5cc08300a.

PMID:
26731288
28.

Structures, physicochemical properties, and applications of T-Hg(II)-T, C-Ag(I)-C, and other metallo-base-pairs.

Tanaka Y, Kondo J, Sychrovský V, Šebera J, Dairaku T, Saneyoshi H, Urata H, Torigoe H, Ono A.

Chem Commun (Camb). 2015 Dec 21;51(98):17343-60. doi: 10.1039/c5cc02693h. Review.

PMID:
26466090
29.

Hg2+-trapping beads: Hg2+-specific recognition through thymine-Hg(II)-thymine base pairing.

Kuriyama M, Haruta K, Dairaku T, Kawamura T, Kikkawa S, Inamoto K, Tsukamoto H, Kondo Y, Torigoe H, Okamoto I, Ono A, Morita EH, Tanaka Y.

Chem Pharm Bull (Tokyo). 2014;62(7):709-12.

30.

Success in making Zn+ from atomic Zn(0) encapsulated in an MFI-type zeolite with UV light irradiation.

Oda A, Torigoe H, Itadani A, Ohkubo T, Yumura T, Kobayashi H, Kuroda Y.

J Am Chem Soc. 2013 Dec 11;135(49):18481-9. doi: 10.1021/ja4077342. Epub 2013 Nov 22.

PMID:
24224580
31.

Further evidence for the existence of a dual-Cu+ site in MFI working as the efficient site for C2H6 adsorption at room temperature.

Itadani A, Sogawa Y, Oda A, Torigoe H, Ohkubo T, Kuroda Y.

Langmuir. 2013 Aug 6;29(31):9727-33. doi: 10.1021/la4018568. Epub 2013 Jul 23.

PMID:
23845166
32.

Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Wada S, Obika S, Shibata MA, Yamamoto T, Nakatani M, Yamaoka T, Torigoe H, Harada-Shiba M.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e45. doi: 10.1038/mtna.2012.32.

33.

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice.

Yamamoto T, Harada-Shiba M, Nakatani M, Wada S, Yasuhara H, Narukawa K, Sasaki K, Shibata MA, Torigoe H, Yamaoka T, Imanishi T, Obika S.

Mol Ther Nucleic Acids. 2012 May 15;1:e22. doi: 10.1038/mtna.2012.16.

34.

A solution 17O-NMR approach for observing an oxidized cysteine residue in Cu,Zn-superoxide dismutase.

Hanashima S, Fujiwara N, Matsumoto K, Iwasaki N, Zheng GQ, Torigoe H, Suzuki K, Taniguchi N, Yamaguchi Y.

Chem Commun (Camb). 2013 Feb 18;49(14):1449-51. doi: 10.1039/c2cc36918d.

PMID:
23323266
35.

Structural switching of Cu,Zn-superoxide dismutases at loop VI: insights from the crystal structure of 2-mercaptoethanol-modified enzyme.

Ihara K, Fujiwara N, Yamaguchi Y, Torigoe H, Wakatsuki S, Taniguchi N, Suzuki K.

Biosci Rep. 2012 Dec;32(6):539-48. doi: 10.1042/BSR20120029.

36.

Thermodynamic and structural properties of the specific binding between Ag⁺ ion and C:C mismatched base pair in duplex DNA to form C-Ag-C metal-mediated base pair.

Torigoe H, Okamoto I, Dairaku T, Tanaka Y, Ono A, Kozasa T.

Biochimie. 2012 Nov;94(11):2431-40. doi: 10.1016/j.biochi.2012.06.024. Epub 2012 Jul 3.

PMID:
22766014
37.

Unprecedented reversible redox process in the ZnMFI-H2 system involving formation of stable atomic Zn(0).

Oda A, Torigoe H, Itadani A, Ohkubo T, Yumura T, Kobayashi H, Kuroda Y.

Angew Chem Int Ed Engl. 2012 Jul 27;51(31):7719-23. doi: 10.1002/anie.201201000. Epub 2012 Jun 22.

PMID:
22730211
38.

Ag(I) ion mediated formation of a C-A mispair by DNA polymerases.

Funai T, Miyazaki Y, Aotani M, Yamaguchi E, Nakagawa O, Wada S, Torigoe H, Ono A, Urata H.

Angew Chem Int Ed Engl. 2012 Jun 25;51(26):6464-6. doi: 10.1002/anie.201109191. Epub 2012 May 29.

PMID:
22644645
39.

2'-O,4'-C-ethylene bridged nucleic acid modification enhances pyrimidine motif triplex-forming ability under physiological condition.

Torigoe H, Sato N, Nagasawa N.

J Biochem. 2012 Jul;152(1):17-26. doi: 10.1093/jb/mvs049. Epub 2012 May 3.

PMID:
22563101
40.

Chemical modification of triplex-forming oligonucleotide to promote pyrimidine motif triplex formation at physiological pH.

Torigoe H, Nakagawa O, Imanishi T, Obika S, Sasaki K.

Biochimie. 2012 Apr;94(4):1032-40. doi: 10.1016/j.biochi.2012.01.003. Epub 2012 Jan 9.

PMID:
22245184
41.

Binding of metal ions by pyrimidine base pairs in DNA duplexes.

Ono A, Torigoe H, Tanaka Y, Okamoto I.

Chem Soc Rev. 2011 Dec;40(12):5855-66. doi: 10.1039/c1cs15149e. Epub 2011 Aug 8. Review.

PMID:
21826352
42.

Behavior of Ag3 clusters inside a nanometer-sized space of ZSM-5 zeolite.

Yumura T, Nanba T, Torigoe H, Kuroda Y, Kobayashi H.

Inorg Chem. 2011 Jul 18;50(14):6533-42. doi: 10.1021/ic2001514. Epub 2011 Jun 21.

PMID:
21692451
43.

Thermodynamic properties of the specific binding between Ag+ ions and C:C mismatched base pairs in duplex DNA.

Torigoe H, Miyakawa Y, Ono A, Kozasa T.

Nucleosides Nucleotides Nucleic Acids. 2011 Feb;30(2):149-67. doi: 10.1080/15257770.2011.553210.

PMID:
21360412
44.

2'-O,4'-C-aminomethylene-bridged nucleic acid modification with enhancement of nuclease resistance promotes pyrimidine motif triplex nucleic acid formation at physiological pH.

Torigoe H, Rahman SM, Takuma H, Sato N, Imanishi T, Obika S, Sasaki K.

Chemistry. 2011 Feb 25;17(9):2742-51. doi: 10.1002/chem.201002745. Epub 2011 Jan 24.

PMID:
21264967
45.

Interrupted 2'-o,4'-C-aminomethylene bridged nucleic acid modification enhances pyrimidine motif triplex-forming ability and nuclease resistance under physiological condition.

Torigoe H, Rahman SM, Takuma H, Sato N, Imanishi T, Obika S, Sasaki K.

Nucleosides Nucleotides Nucleic Acids. 2011 Jan;30(1):63-81. doi: 10.1080/15257770.2010.543118.

PMID:
21259164
46.

Hg(II) ion specifically binds with T:T mismatched base pair in duplex DNA.

Torigoe H, Ono A, Kozasa T.

Chemistry. 2010 Nov 22;16(44):13218-25. doi: 10.1002/chem.201001171.

PMID:
20886468
47.

Site-specific Xe additions into Cu-ZSM-5 zeolite.

Yumura T, Yamashita H, Torigoe H, Kobayashi H, Kuroda Y.

Phys Chem Chem Phys. 2010 Mar 14;12(10):2392-400. doi: 10.1039/b919032e. Epub 2010 Jan 19.

PMID:
20449352
48.

Interaction between tetraplex structure of mouse telomeric DNA and telomeric DNA binding domains of mouse telomere binding protein Pot1.

Kaneda K, Torigoe H.

Nucleic Acids Symp Ser (Oxf). 2009;(53):245-6. doi: 10.1093/nass/nrp123.

PMID:
19749352
49.

Interaction between tetraplex structure of yeast telomeric DNA and tetraplex-binding ligand.

Torigoe H, Horio E, Takehara T, Kaneda K, Kozasa T.

Nucleic Acids Symp Ser (Oxf). 2009;(53):243-4. doi: 10.1093/nass/nrp122.

PMID:
19749351
50.

Tetraplex structure of budding yeast telomeric DNA.

Torigoe H, Horio E, Takehara T, Kaneda K, Kozasa T.

Nucleic Acids Symp Ser (Oxf). 2009;(53):235-6. doi: 10.1093/nass/nrp118.

PMID:
19749347

Supplemental Content

Loading ...
Support Center